March 5, 2026 — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a forward-thinking biopharmaceutical company specializing in immuno-dermatology, has announced the promotion of Mas Matsuda to the role of Executive Vice President and Chief Legal Officer. This strategic move is aimed at bolstering the company's legal, compliance, and governance frameworks as it prepares for a new phase of growth and the commercialization of its flagship product, ZORYVE® (roflumilast).

1. A Leader in Legal Compliance

Mas Matsuda, JD, previously served as Senior Vice President and General Counsel, a role in which he played a pivotal part in guiding Arcutis through a period of significant commercial growth. Since joining the company in January 2022, Mr. Matsuda has been instrumental in securing six FDA approvals for the ZORYVE portfolio and in establishing a robust legal and compliance framework that supports the company’s ambitious goals.

Frank Watanabe, President and CEO of Arcutis, expressed enthusiasm regarding Matsuda's promotion, highlighting his trusted advisement and leadership qualities. "Mas has been a trusted adviser and an instrumental leader, strengthening our legal and compliance foundation while supporting the successful development and growth of ZORYVE. As we highlighted in our recent fourth quarter and full-year results, Arcutis is entering an exciting next phase of growth," Watanabe noted.

2. A Strong Foundation for Future Growth

Matsuda's extensive experience includes serving as Senior Vice President and General Counsel at Halozyme Therapeutics, Inc., along with various legal positions at Amgen. His knowledge and expertise in corporate governance will be crucial as Arcutis aims to expand its commercial presence in the dermatology market.

In his own words, Matsuda expressed pride in contributing to Arcutis's momentum and emphasized the company's role in delivering innovative solutions for individuals suffering from immune-mediated skin diseases. "Over the past four years, Arcutis has evolved into a leader in medical dermatology with a successful ZORYVE franchise and an advancing pipeline," he stated. "I look forward to working alongside our leadership team as we enter the next phase of growth, delivering meaningful innovation for individuals suffering from immune-mediated skin diseases."

3. ZORYVE®: A Game Changer in Dermatology

ZORYVE is a groundbreaking treatment available in various formulations, including creams and foams, aimed at addressing different types of dermatological conditions. The product portfolio includes:

ZORYVE cream, 0.05%: For mild to moderate atopic dermatitis in patients aged 2-5.

ZORYVE cream, 0.15%: For mild to moderate atopic dermatitis in patients aged 6 and older.

ZORYVE cream, 0.3%: For plaque psoriasis in patients aged 6 and older.

ZORYVE topical foam, 0.3%: For plaque psoriasis of the scalp and body in patients aged 12 and older, and for seborrheic dermatitis in those aged 9 and older.

4. Looking Ahead

Arcutis is poised for an exciting future with Matsuda at the helm of its legal and governance strategies. As the company pushes forward with its commercialization efforts and continues to develop its innovative product pipeline, Matsuda's leadership will be vital in navigating the complexities of the biopharmaceutical landscape.

With its commitment to addressing urgent dermatological needs, Arcutis Biotherapeutics remains a key player in the field, striving for sustained growth and long-term success.

For further information about Arcutis and its innovative therapies, visit their website or follow them on their social media platforms.

Original press release